OTC Drugs: U.S. Competitor Cost Structures

Digital Media, Gummy Product Forms, and Mergers Impact OTC Cost Structures

The OTC industry continues to consolidate and transform itself with companies merging or acquiring/divesting brands. Recent examples include the merger of Bayer’s and Merck’s OTC businesses, the joint venture between GlaxoSmithKline’s and Novartis’ consumer health units, and Sanofi’s upcoming acquisition of Boehringer-Ingelheim’s OTC unit. With acquisitions come synergies, such as more media buying power, widened retail distribution, and competitive strengths across more OTC categories. However, mergers and joint ventures can also lead to increased costs of raw materials, packaging, and processing to manufacture a larger array of products. Increased marketing expenditures in support of newly acquired brands also impacts profitability, with the longer term goal of increasing sales and market share. Sales growth of acquired brands can help offset additional costs in cost of goods sold (COGS) and marketing. Continue reading

Rx-to-OTC Switch Forecasting Model

New Data Shows Plenty of Room for Innovators of All Sizes in OTC Market

The over-the-counter drug market is heating up as consumers turn increasingly toward self-medication in an effort to minimize out-of-pocket healthcare costs. With increasing competition from private-label products, blockbuster switches, and somewhat unconventional entries into the OTC drug business, new data reveals that while innovation doesn’t necessarily equate to superb business performance, there is plenty of room for players of all sizes and shapes in the nonprescription drugs market. More…Continue reading